National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding autoimmune hemolytic anemia (AIHA), a condition where the body’s immune system mistakenly attacks and destroys its own red blood cells, leading to anemia (low levels of hemoglobin). The study aims to find out how common AIHA is, what factors might contribute to its development, and how effective different treatments are for patients. Researchers will collect information on patients’ backgrounds, health conditions, and treatment results, while also looking at how these factors impact overall health and quality of life over time.

To participate in the trial, individuals must have a diagnosis of AIHA and have low hemoglobin levels (less than 100g/L). They should have received treatment at a specific hospital since January 1, 2001. Participants will be closely monitored for their health outcomes, including how well they respond to treatment and any potential relapses of the disease. It's important to note that individuals with significant health issues or substance dependence may not be eligible to join the study. Overall, this trial aims to provide valuable insights that could improve care for patients with AIHA in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects diagnosed with AIHA.
• • Hemoglobin\<100g/L
• • Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2001.
• Exclusion Criteria:
• • Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities).
• • Subject with alcohol or drug dependence may reduce their compliance with the study.
• • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.